Gilead Sciences (GILD) EBIT Margin Growth (5y) (2014 - 2026)

Gilead Sciences (GILD) EBIT Margin Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -784.00
Dec 31, 2025 -1,069.00
Sep 30, 2025 1,240.00
Jun 30, 2025 9,293.00
Mar 31, 2025 -974.00
Dec 31, 2024 1,380.00
Sep 30, 2024 3,805.00
Jun 30, 2024 -472.00
Mar 31, 2024 -10,700.00
Dec 31, 2023 292.00
Sep 30, 2023 -967.00
Jun 30, 2023 -1,514.00
Mar 31, 2023 -1,547.00
Dec 31, 2022 1,933.00
Sep 30, 2022 -1,825.00
Jun 30, 2022 -2,716.00
Mar 31, 2022 -5,492.00
Dec 31, 2021 -4,228.00
Sep 30, 2021 -688.00
Jun 30, 2021 -2,223.00